Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial

Medicine and Dentistry

• Patient 100%
• Cardiomyopathy 100%
• Anthracycline 100%
• Heart Failure 100%
• Cell Therapy 100%
• Mesenchymal Stem Cell 50%
• Cardiac Magnetic Resonance Imaging 33%
• Malignant Neoplasm 16%
• Injection 16%
• Woman 16%
• Inpatient 16%
• Therapeutic Procedure 8%
• Cells 8%
• Quality of Life 8%
• Stem Cell 8%
• Age 8%
• Follow up 8%
• Young Adult 8%
• Prognosis 8%
• Neoplasm 8%
• Biological Marker 8%
• Heart Function 8%
• Functional Status 8%
• Six Minute Walk Test 8%

Biochemistry, Genetics and Molecular Biology

• Anthracycline 100%
• Bone 100%
• Stromal Cell 50%
• Cardiac Magnetic Resonance Imaging 33%
• Human Study 16%
• Stem Cell 8%
• Age 8%
• Life 8%
• Dose 8%
• Heart Function 8%
• Functional Status 8%